 Nancy Madinger
Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trench Fever | 1 | 2022 | 5 | 0.750 |
Why?
| | Bartonella quintana | 1 | 2022 | 5 | 0.750 |
Why?
| | Endocarditis | 1 | 2022 | 40 | 0.720 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 260 | 0.560 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.480 |
Why?
| | Strongyloidiasis | 1 | 2016 | 4 | 0.480 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.480 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 24 | 0.480 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.470 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.470 |
Why?
| | Sexual Behavior | 1 | 2019 | 496 | 0.430 |
Why?
| | Program Evaluation | 1 | 2019 | 945 | 0.430 |
Why?
| | Anemia | 1 | 2016 | 190 | 0.420 |
Why?
| | Klebsiella Infections | 1 | 2014 | 26 | 0.410 |
Why?
| | Carbapenems | 1 | 2014 | 27 | 0.410 |
Why?
| | Klebsiella pneumoniae | 1 | 2014 | 47 | 0.410 |
Why?
| | beta-Lactamases | 1 | 2014 | 53 | 0.400 |
Why?
| | Rectum | 1 | 2014 | 183 | 0.370 |
Why?
| | Curriculum | 1 | 2019 | 1068 | 0.350 |
Why?
| | Disease Outbreaks | 1 | 2014 | 426 | 0.320 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2021 | 81 | 0.310 |
Why?
| | Methicillin | 1 | 2009 | 10 | 0.290 |
Why?
| | Internship and Residency | 1 | 2019 | 1265 | 0.270 |
Why?
| | Anti-Bacterial Agents | 6 | 2021 | 1953 | 0.270 |
Why?
| | Platelet Transfusion | 1 | 2009 | 78 | 0.270 |
Why?
| | HIV Infections | 2 | 2022 | 3189 | 0.260 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 268 | 0.250 |
Why?
| | Enterobacteriaceae | 2 | 2021 | 44 | 0.240 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 206 | 0.230 |
Why?
| | Rhizopus | 1 | 2005 | 3 | 0.220 |
Why?
| | Immunoglobulin G | 2 | 2022 | 890 | 0.220 |
Why?
| | Facial Pain | 1 | 2005 | 12 | 0.220 |
Why?
| | Blood Platelets | 1 | 2009 | 380 | 0.220 |
Why?
| | Mucormycosis | 1 | 2005 | 18 | 0.220 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 455 | 0.210 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.200 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 420 | 0.200 |
Why?
| | Mycoses | 1 | 2003 | 88 | 0.190 |
Why?
| | Sinusitis | 1 | 2005 | 227 | 0.180 |
Why?
| | Brain Diseases | 1 | 2003 | 153 | 0.180 |
Why?
| | Peptide Nucleic Acids | 1 | 2021 | 3 | 0.170 |
Why?
| | Enterobacteriaceae Infections | 1 | 2021 | 42 | 0.160 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 118 | 0.160 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 21 | 0.160 |
Why?
| | Cryptococcosis | 1 | 2020 | 31 | 0.160 |
Why?
| | Cross Infection | 2 | 2009 | 264 | 0.150 |
Why?
| | Drug Design | 1 | 2021 | 176 | 0.150 |
Why?
| | Bacteria | 2 | 2017 | 897 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 5 | 2021 | 378 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2005 | 700 | 0.140 |
Why?
| | Antifungal Agents | 3 | 2020 | 150 | 0.140 |
Why?
| | Superoxides | 1 | 2017 | 199 | 0.120 |
Why?
| | Humans | 25 | 2022 | 145491 | 0.120 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.120 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.120 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.120 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.120 |
Why?
| | Ivermectin | 1 | 2016 | 14 | 0.120 |
Why?
| | Female | 14 | 2022 | 78763 | 0.120 |
Why?
| | Xanthomonas | 1 | 1996 | 2 | 0.120 |
Why?
| | Hematocrit | 1 | 2016 | 108 | 0.120 |
Why?
| | Computational Biology | 1 | 2021 | 687 | 0.120 |
Why?
| | Acinetobacter | 1 | 1996 | 16 | 0.120 |
Why?
| | Pseudomonas | 1 | 1996 | 33 | 0.120 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2009 | 251 | 0.120 |
Why?
| | Quantum Dots | 1 | 2016 | 37 | 0.120 |
Why?
| | Adult | 10 | 2020 | 40707 | 0.120 |
Why?
| | Anthelmintics | 1 | 2015 | 12 | 0.120 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1996 | 49 | 0.110 |
Why?
| | Feces | 2 | 2015 | 514 | 0.110 |
Why?
| | o-Phthalaldehyde | 1 | 2014 | 3 | 0.110 |
Why?
| | Glutaral | 1 | 2014 | 14 | 0.110 |
Why?
| | Middle Aged | 8 | 2022 | 36176 | 0.100 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1994 | 29 | 0.100 |
Why?
| | Staphylococcal Infections | 2 | 2009 | 391 | 0.100 |
Why?
| | Migraine Disorders | 1 | 2016 | 115 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 908 | 0.100 |
Why?
| | Bacterial Infections | 2 | 2011 | 247 | 0.100 |
Why?
| | Disinfectants | 1 | 2014 | 50 | 0.100 |
Why?
| | Male | 12 | 2022 | 72817 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2020 | 676 | 0.100 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 120 | 0.100 |
Why?
| | Hemoglobins | 1 | 2016 | 386 | 0.100 |
Why?
| | Administration, Oral | 1 | 2016 | 863 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2014 | 331 | 0.100 |
Why?
| | Genital Diseases, Female | 1 | 1993 | 31 | 0.100 |
Why?
| | Bacteria, Anaerobic | 1 | 1993 | 25 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 357 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2014 | 210 | 0.090 |
Why?
| | Azithromycin | 1 | 2011 | 105 | 0.080 |
Why?
| | Population Surveillance | 1 | 2014 | 485 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1544 | 0.080 |
Why?
| | Daptomycin | 1 | 2009 | 18 | 0.080 |
Why?
| | Technology Assessment, Biomedical | 1 | 1989 | 44 | 0.070 |
Why?
| | Young Adult | 3 | 2015 | 14192 | 0.070 |
Why?
| | Vancomycin | 1 | 2009 | 94 | 0.070 |
Why?
| | Th1 Cells | 1 | 2009 | 139 | 0.070 |
Why?
| | Intensive Care Units | 1 | 2014 | 925 | 0.070 |
Why?
| | Pregnancy | 3 | 2016 | 7197 | 0.060 |
Why?
| | Bacterial Proteins | 1 | 1994 | 991 | 0.060 |
Why?
| | Animals | 4 | 2021 | 38141 | 0.060 |
Why?
| | Bacteremia | 1 | 2009 | 223 | 0.060 |
Why?
| | Pregnancy Outcome | 1 | 1989 | 497 | 0.060 |
Why?
| | Cytosine | 1 | 2005 | 49 | 0.060 |
Why?
| | Aged | 5 | 2020 | 26125 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2009 | 499 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 36 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 97 | 0.050 |
Why?
| | Drug Resistance, Microbial | 2 | 1996 | 71 | 0.050 |
Why?
| | Herpes Simplex | 1 | 2005 | 98 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 919 | 0.050 |
Why?
| | Colorado | 1 | 2014 | 4572 | 0.050 |
Why?
| | Autopsy | 1 | 2003 | 95 | 0.050 |
Why?
| | Pregnancy Complications | 1 | 1989 | 612 | 0.050 |
Why?
| | Pneumonia | 1 | 1989 | 632 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 675 | 0.050 |
Why?
| | Liposomes | 1 | 2005 | 259 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 171 | 0.050 |
Why?
| | Oxidation-Reduction | 2 | 2017 | 1080 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 306 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2020 | 11831 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 1138 | 0.050 |
Why?
| | Cholangitis | 1 | 2002 | 22 | 0.040 |
Why?
| | Peritoneal Dialysis, Continuous Ambulatory | 1 | 2001 | 16 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2021 | 48 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2021 | 156 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 89 | 0.040 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2002 | 103 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | Peritonitis | 1 | 2001 | 83 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 91 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 23 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2002 | 230 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 232 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 222 | 0.040 |
Why?
| | Fetal Blood | 1 | 2002 | 325 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2005 | 772 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 633 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2020 | 202 | 0.040 |
Why?
| | Medication Adherence | 1 | 2022 | 543 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 648 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2020 | 251 | 0.030 |
Why?
| | Cytotoxins | 1 | 1994 | 15 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2017 | 326 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1994 | 109 | 0.030 |
Why?
| | Gram-Negative Anaerobic Bacteria | 1 | 1993 | 2 | 0.020 |
Why?
| | Gram-Positive Bacteria | 1 | 1993 | 49 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2022 | 17269 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 2002 | 1173 | 0.020 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1992 | 130 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1047 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 519 | 0.020 |
Why?
| | Nasopharynx | 1 | 2011 | 73 | 0.020 |
Why?
| | Macrolides | 1 | 2011 | 69 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1992 | 171 | 0.020 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1989 | 4 | 0.020 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2009 | 23 | 0.020 |
Why?
| | Adolescent | 3 | 2022 | 22485 | 0.020 |
Why?
| | New York City | 1 | 1989 | 89 | 0.020 |
Why?
| | Obstetric Labor, Premature | 1 | 1989 | 39 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2014 | 372 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 54 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 73 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 178 | 0.020 |
Why?
| | Infant Mortality | 1 | 1989 | 128 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2009 | 440 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 347 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 177 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 244 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2009 | 782 | 0.010 |
Why?
| | Simplexvirus | 1 | 2005 | 82 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2009 | 1134 | 0.010 |
Why?
| | Risk Factors | 2 | 2009 | 10874 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 124 | 0.010 |
Why?
| | United States | 2 | 2014 | 16115 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 297 | 0.010 |
Why?
| | Mice | 1 | 2021 | 18338 | 0.010 |
Why?
| | Length of Stay | 1 | 1989 | 1348 | 0.010 |
Why?
| | Bile Duct Diseases | 1 | 2002 | 13 | 0.010 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2002 | 63 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2002 | 89 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 2002 | 252 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2499 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4127 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 316 | 0.010 |
Why?
| | Drainage | 1 | 2002 | 185 | 0.010 |
Why?
| | Treatment Failure | 1 | 2002 | 365 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 168 | 0.010 |
Why?
| | Graft Survival | 1 | 2002 | 519 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 373 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 8039 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5992 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 1119 | 0.010 |
Why?
| | Chronic Disease | 1 | 2002 | 1816 | 0.010 |
Why?
| | Neutrophils | 1 | 2002 | 1124 | 0.010 |
Why?
| | Lung Diseases | 1 | 2002 | 783 | 0.010 |
Why?
| | Suppuration | 1 | 1992 | 9 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2001 | 1585 | 0.010 |
Why?
| | Catalase | 1 | 1992 | 133 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2373 | 0.000 |
Why?
| | Infant | 1 | 2002 | 10064 | 0.000 |
Why?
| | Child, Preschool | 1 | 2002 | 11837 | 0.000 |
Why?
| | Child | 1 | 2002 | 22680 | 0.000 |
Why?
|
|
Madinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|